Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Return on Capital Employed (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Return on Capital Employed for 5 consecutive years, with 1.76% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Return on Capital Employed fell 148.0% year-over-year to 1.76%, compared with a TTM value of 1.76% through Jun 2025, down 148.0%, and an annual FY2025 reading of 0.5%, up 26.0% over the prior year.
  • Return on Capital Employed was 1.76% for Q2 2025 at SAB Biotherapeutics, down from 1.05% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.19% in Q1 2024 and bottomed at 1.76% in Q2 2025.
  • Average Return on Capital Employed over 5 years is 0.72%, with a median of 0.71% recorded in 2022.
  • The sharpest move saw Return on Capital Employed soared 77bps in 2024, then plummeted -148bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.26% in 2021, then plummeted by -205bps to 0.79% in 2022, then surged by 75bps to 0.2% in 2023, then crashed by -435bps to 1.05% in 2024, then tumbled by -68bps to 1.76% in 2025.
  • Business Quant data shows Return on Capital Employed for SABS at 1.76% in Q2 2025, 1.05% in Q4 2024, and 0.46% in Q3 2024.